Literature DB >> 22697420

The right compound in the right assay at the right time: an integrated discovery DMPK strategy.

Peter Ballard1, Patrick Brassil, Khanh H Bui, Hugues Dolgos, Carl Petersson, Anders Tunek, Peter J H Webborn.   

Abstract

The high rate of attrition during drug development and its associated high research and development (R&D) cost have put pressure on pharmaceutical companies to ensure that candidate drugs going to clinical testing have the appropriate quality such that the biological hypothesis could be evaluated. To help achieve this ambition, drug metabolism and pharmacokinetic (DMPK) science and increasing investment have been deployed earlier in the R&D process. To gain maximum return on investment, it is essential that DMPK concepts are both appropriately integrated into the compound design process and that compound selection is focused on accurate prediction of likely outcomes in patients. This article describes key principles that underpin the contribution of DMPK science for small-molecule research based on 15 years of discovery support in a major pharmaceutical company. It does not aim to describe the breadth and depth of DMPK science, but more the practical application for decision making in real-world situations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22697420     DOI: 10.3109/03602532.2012.691099

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  12 in total

1.  Time dependent analysis of assay comparability: a novel approach to understand intra- and inter-site variability over time.

Authors:  Susanne Winiwarter; Brian Middleton; Barry Jones; Paul Courtney; Bo Lindmark; Ken M Page; Alan Clark; Claire Landqvist
Journal:  J Comput Aided Mol Des       Date:  2015-02-20       Impact factor: 3.686

2.  Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery.

Authors:  N Gobeau; R Stringer; S De Buck; T Tuntland; B Faller
Journal:  Pharm Res       Date:  2016-06-08       Impact factor: 4.200

3.  Impact of a five-dimensional framework on R&D productivity at AstraZeneca.

Authors:  Paul Morgan; Dean G Brown; Simon Lennard; Mark J Anderton; J Carl Barrett; Ulf Eriksson; Mark Fidock; Bengt Hamrén; Anthony Johnson; Ruth E March; James Matcham; Jerome Mettetal; David J Nicholls; Stefan Platz; Steve Rees; Michael A Snowden; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2018-01-19       Impact factor: 84.694

Review 4.  Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.

Authors:  Christopher R Jones; Oliver J D Hatley; Anna-Lena Ungell; Constanze Hilgendorf; Sheila Annie Peters; Amin Rostami-Hodjegan
Journal:  AAPS J       Date:  2016-03-10       Impact factor: 4.009

5.  Anti-Leishmania infantum in vitro effect of n-cyclohexyl-1,2,4-oxadiazole and its ADME/TOX parameters.

Authors:  Cristian Vicson Gomes Pinheiro; Wildson Max Barbosa da Silva; João Pedro Viana Rodrigues; Yasmim Mendes Rocha; Maria Jania Teixeira; Ronaldo Nascimento de Oliveira; Natália Vasconcelos de Souza; Roberto Nicolete
Journal:  J Parasit Dis       Date:  2021-10-06

Review 6.  Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models.

Authors:  Sheila Annie Peters; Christopher R Jones; Anna-Lena Ungell; Oliver J D Hatley
Journal:  Clin Pharmacokinet       Date:  2016-06       Impact factor: 6.447

7.  A comparative evaluation of models to predict human intestinal metabolism from nonclinical data.

Authors:  Estelle Yau; Carl Petersson; Hugues Dolgos; Sheila Annie Peters
Journal:  Biopharm Drug Dispos       Date:  2017-04       Impact factor: 1.627

Review 8.  Current status and future directions of high-throughput ADME screening in drug discovery.

Authors:  Wilson Z Shou
Journal:  J Pharm Anal       Date:  2020-05-23

9.  A Fully Integrated Assay Panel for Early Drug Metabolism and Pharmacokinetics Profiling.

Authors:  Johan Wernevik; Fredrik Bergström; Anna Novén; Johan Hulthe; Linda Fredlund; Dan Addison; Jan Holmgren; Per-Erik Strömstedt; Erika Rehnström; Thomas Lundböck
Journal:  Assay Drug Dev Technol       Date:  2020-05-14       Impact factor: 1.738

10.  Random Forest Model Prediction of Compound Oral Exposure in the Mouse.

Authors:  Haseeb Mughal; Han Wang; Matthew Zimmerman; Marc D Paradis; Joel S Freundlich
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.